J-PAL North America and Results for America announce 18 collaborations with state and local governments

Organizations will support government agencies in using evidence to advance economic mobility and racial equity in the wake of Covid-19.

J-PAL North America and Results for America have announced 18 new partnerships with state and local governments across the country through their Leveraging Evidence and Evaluation for Equitable Recovery (LEVER) programming, which launched in April of this year. 

As state and local leaders leverage federal relief funding to invest in their communities, J-PAL North America and Results for America are providing in-depth support to agencies in using data, evaluation, and evidence to advance effective and equitable government programming for generations to come. The 18 new collaborators span the contiguous United States and represent a wide range of pressing and innovative uses of federal Covid-19 recovery Connecticut’s Medicaid office, operating out of the state’s Department of Social Services , is working to improve vaccine access and awareness among youth. "Connecticut Medicaid is thrilled to work with J-PAL North America. The technical expertise and training that we receive will expand our knowledge during ’testing and learning’ interventions that improve the health of our members," says Gui Woolston, the director of Medicaid and Division of Health Fourteen additional state and local agencies are working with Results for America as part of the LEVER Training Sprint. Together, they will develop policies that catalyze sustainable evidence building within government. 

Jurisdictions selected for the Training Sprint represent government leaders at the city, county, and state levels - all of whom are committed to creating an evaluation framework for policy that will prioritize evidence-based decision-making across the country. Over the course of 10 weeks, with access to tools and coaching, each team will develop an internal implementation policy by embedding key evaluation and evidence practices into their jurisdiction’s decision-making processes. Participants will finish the Training Sprint with a robust decision-making framework that translates their LEVER implementation policies into actionable planning guidance. 

Government leaders will utilize the LEVER Training Sprint to build a culture of data and evidence focused on leveraging evaluation policies to invest in delivering tangible results for their residents. About their participation in the LEVER Training Sprint, Dana Williams from Denver, Colorado says, "Impact evaluation is such an integral piece to understanding the past, present, and future. I’m excited to participate in the LEVER Training Sprint to better inform and drive evidence-based programming in Denver."

The Training Sprint is a part of a growing movement to ground government innovation in data and evidence. Kermina Hanna from the State of New Jersey notes, "It’s vital that we cement a data-driven commitment to equity in government operations, and I’m really excited for this opportunity to develop a national network of colleagues in government who share this passion and dedication to responsive public service."

Jurisdictions selected for the Training Sprint are: 
  • Boston, Massachusetts;
  • Carlsbad, California;
  • Connecticut;
  • Dallas, Texas;
  • Denver City/County, Colorado;
  • Fort Collins, Colorado;
  • Guilford County, North Carolina;
  • King County, Washington;
  • Long Beach, California;
  • Los Angeles, California;
  • New Jersey;
  • New Mexico;
  • Pittsburgh, Pennsylvania; and
  • Washington County, Oregon.


Those interested in learning more can fill out the LEVER intake form. Please direct any questions about the Evaluation Incubator to Louise Geraghty and questions about the Training Sprint to Chelsea Powell.

Related Links

Related Topics

Related Articles

MIT spinout Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new drug targets.

In campus talk, Daron Acemoglu offers vision of "machine usefulness," rather than autonomous "intelligence," to help workers and spread prosperity.

By analyzing epigenomic and gene expression changes that occur in Alzheimer’s disease, researchers identify cellular pathways that could become new drug targets.